🧬 Biotech + New York, NY
Biotech Venture Capital Firms in New York, NY
Discover 6 venture capital firms investing in Biotech and headquartered in New York, NY. This directory highlights investors with active biotech portfolios and a local presence in New York, NY, helping founders identify the right capital partners for their next raise. Browse firm profiles, compare check sizes and stage focus, and find investors who understand both the biotech landscape and the New York, NY startup ecosystem.
6 firms
Frequently Asked Questions
What are the best Biotech VC firms in New York, NY?
New York, NY is home to 6+ venture capital firms that specialize in Biotech. The top firms combine deep Biotech expertise with local New York, NY networks, deal flow, and industry connections.
How do I find a Biotech investor in New York, NY?
Start by reviewing the 6 Biotech-focused VCs based in New York, NY ranked on this page. Evaluate each firm's stage focus, check size, and portfolio to find the best fit for your startup's needs.
Is New York, NY a good place to raise Biotech funding?
New York, NY has an active Biotech investment community with firms specializing in this sector. Local investors bring valuable industry connections and ecosystem advantages specific to the New York, NY market.
2048 Ventures
New York, NYPre-seed firm guaranteeing funds in 10 business days.
Lux Capital
New York, NYDeep technology venture firm investing in emerging science and technology ventures in energy, healthcare, and defense.
OrbiMed Advisors
New York, NYHealthcare-only platform spanning seed through IPO via public/private arms.
Pfizer Ventures
New York, NYPfizer Ventures is the venture capital arm of Pfizer, investing in biotech companies in oncology, inflammation and immunology, cardiometabolic disease, vaccines and next-generation modalities.
Venrock Healthcare
New York, NYHealthcare-focused venture arm of Venrock, the Rockefeller family venture fund, investing in biotech and digital health.
Thrive Capital
New York, NYThrive Capital is a New York venture capital firm founded by Joshua Kushner in 2009. It invests from seed through late-stage growth rounds, mostly in software, AI, fintech and frontier technology. In February 2026 it closed Thrive X at more than $10 billion, split into $1 billion for early-stage investments and $9 billion for growth-stage investments.